Estudios Clinicos - [Instituto CER]

Estudios Clínicos en CER

= Estudios abiertos en busca de pacientes.

= Estudios en curso.

= Estudios finalizados.

= Material de Lectura / Información del estudio.

Estudios Clinicos Activos

Estudio	Año	Patología	Sponsor	Más

Estudios Finalizados

Estudio	Año	Patología	Sponsor
To assess the efficacy and safety of LY2127399 in patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF-α inhibitors	2011	AR	ELI LILLY
To assess the long-term safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA)	2011	AR	ELI LILLY
Multinational, multicenter, non-interventional study in patients with rheumatoid arthritis (RA) treated with tocilizumab	2011	AR	ROCHE
To evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) compared to etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis	2012	AR	ROCHE
Ptes treated with tocilizumab	2012	AR	SANOFI ADVENTIS
Record longitudinal results and cardiovascular comorbidities	2012	AR	CORRONA
International record of longitudinal results and cardiovascular comorbidities in patients with rheumatoid arthritis	2012	AR
To assess the relative efficacy and tolerability of two doses Of MK 0663 / etoricoxib in patients with arthritis Rheumatoid	2013	AR	MERCK
To assess the efficacy and safety of baricitinib in patients with moderate to severe active rheumatoid arthritis who have failed to respond to methotrexate therapy	2013	AR	ELI LILLY
To assess the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis who have received limited or no treatment with antirheumatic drug-modifying drugs	2013	AR	ELI LILLY

Estudio	Año	Patología	Sponsor
To assess the efficacy and safety of LY2127399 in patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF-α inhibitors	2011	AR	ELI LILLY
To assess the long-term safety and efficacy of LY2127399 in patients with rheumatoid arthritis (RA)	2011	AR	ELI LILLY
Multinational, multicenter, non-interventional study in patients with rheumatoid arthritis (RA) treated with tocilizumab	2011	AR	ROCHE
To evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) compared to etanercept (ETA) on the rate of cardiovascular events in patients with moderate to severe rheumatoid arthritis	2012	AR	ROCHE
Ptes treated with tocilizumab	2012	AR	SANOFI ADVENTIS
Record longitudinal results and cardiovascular comorbidities	2012	AR	CORRONA
International record of longitudinal results and cardiovascular comorbidities in patients with rheumatoid arthritis	2012	AR
To assess the relative efficacy and tolerability of two doses Of MK 0663 / etoricoxib in patients with arthritis Rheumatoid	2013	AR	MERCK
To assess the efficacy and safety of baricitinib in patients with moderate to severe active rheumatoid arthritis who have failed to respond to methotrexate therapy	2013	AR	ELI LILLY
To assess the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis who have received limited or no treatment with antirheumatic drug-modifying drugs	2013	AR	ELI LILLY
To assess the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis and insufficient response to conventional disease modifying antirheumatic drugs	2013	AR	ELI LILLY
Efficacy, pharmacokinetics and safety of BI 695500 against rituximab in patients with moderate to severe active rheumatoid arthritis: randomized, double-blind, parallel-group, multiple-dose and active comparator	2013	AR	BOHERINGER E
Multicenter, uncontrolled extension study evaluating the efficacy and safety of SAR153191 added to DMARD in patients with active rheumatoid arthritis (RA)	2013	AR	SANOFI ADVENTIS
To assess the safety and long-term efficacy of baricitinib in patients with rheumatoid arthritis	2014	AR	ELI LILLY
Alendronate controlled double-blind, multicenter, international, randomized trial to determine the efficacy and safety of AMG 785 in the Treatment of Postmenopausal Women with Osteoporosis.	2014	OTP	AMGEN
Phase 3 randomized, double-blind, placebo-controlled, active drug trial to evaluate the efficacy and safety of baricitinib in patients with moderate to severe active rheumatoid arthritis who have failed to respond adequately to methotrexate	2014	AR	ELI LILLY
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis and insufficient response to conventional disease-modifying antirheum	2014	AR	ELI LILLY
A Phase 3 randomized, double-blind, active-controlled study to evaluate the efficacy and safety of baricitinib (LY3009104) in patients with moderate to severe active rheumatoid arthritis who have received limited or no treatment with antirheumatic drugs	2014	AR	ELI LILLY
Phase 3 multicenter study to evaluate the safety and long-term efficacy of baricitinib in patients with rheumatoid arthritis	2015	AR	ELI LILLY
Multicenter, open-label, long-term follow-up study of the safety and efficacy of GLPG0634 in patients with moderate to severe active rheumatoid arthritis	2015	AR	GALAPAGOS
A randomized, double-blind, placebo-controlled, double-blind, phase IIb study administered for 24 weeks in combination with methotrexate in patients with moderate to severe active rheumatoid arthritis who had an inadequate response to methotrexate alone	2015	AR	GALAPAGOS
A randomized, double-blind, placebo-controlled, active-principle study of DS-5565 in patients with pain associated with fibromyalgia	2016	Fibromyalgia	DAICHI
A randomized, double-blind, placebo-controlled, active-principle study of DS-5565 in patients with pain associated with fibromyalgia	2016	AR	GEMA BIOTECH
Multicenter, double-blind, randomized study of denosumab versus zoledronic acid (Zometa®) for the treatment of bone metastases	2006	Advanced cancer (except breast and prostate cancer) or multiple myeloma	AMGEN INC
Open, randomized, multicenter study with two parallel branches to evaluate drug E7389 versus treatment of choice of physician	2007	Metastasic or locally recurrent breast cancer, previously treated with at least two and a maximum of 5 previous chemotherapeutic treatments, which included an anthracycline and a taxane	Eisai / ICON
A randomized, multicenter, open-label, phase III study of lapatinib, adjuvant trastuzumab, its sequence and combination	2007	Subjects suffering from her2 / erb2 positive primary breast cáncer	GlaxoSmithKline
An open-label extension study evaluating the safety and efficacy of Pazopanib	2007	Subjects with renal cell carcinoma previously incorporated into Protocol VEG105192	Hoffmann – La Roche LTD
Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind, AMG 706 Combined with Paclitaxel and Carboplatin	2008	Advanced Non Small Cell Lung Cancer	AMGEN INC
A multicenter, randomized, double-blind, Phase III study to investigate the efficacy and safety of oral BIBF 1120 plus standard treatment with pemetrexed Compared with placebo plus standard pemetrexed treatment	2008	Lung cancer to non-small cell stage IIIB / IV or recurrent after failure of first-line chemotherapy	Boehringer Ingelheim
A study evaluating the activity and safety of cetuximab as a maintenance treatment with 250 mg / m2 per week and 500 mg / m2 every two weeks after platinum-based chemotherapy in combination with cetuximab as a first-line treatment	2008	Subjects with advanced non-small cell lung cáncer	MERCK
A randomized, multicenter, open-label, phase III study of lapatinib, trastuzumab and its combination in neoadyuvancy plus paclitaxel	2008	Women with HER2 / ErB2 positive primary breast cáncer	GlaxoSmithKline
Phase III randomized, double-blind, placebo-controlled study to evaluate the efficacy of recMAGE-A3 + Antineoplastic Specific Immunotherapeutic Antineoplastic Antigen (AIAE) AS15 as adjuvant therapy	2008	Subjects with non-small cell lung cancer MAGE-A3 resectable positive	GlaxoSmithKline
Phase II randomized study of oral vinorelbine combination with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first-line chemotherapy	2008	Patients with metastatic breast cancer	PIERRE FABRE (ROVAFARM ARGENTINA S. A.)
Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Pertuzumab + Trastuzumab + Docetaxel versus placebo + Trastuzumab + Docetaxel	2009	HER2 positive metastatic breast cancer, previously untreated	Hoffmann – La Roche LTD
Open-label phase 2, randomized, active-controlled study of CS-7017 in combination with FOLFIRI	2010	Metastatic colorectal cancer that failed first line therapy	ICON
Randomized, Open, Multicenter, Phase 3, Epoetin Alfa plus Standard Support Therapy Versus Standard Support Therapy in Anemic Patients	2010	Metastatic Breast Cancer Receiving Standard Chemotherapy	Johnson & Jhonson
Randomized, double-blind, placebo-controlled study of PF-804	2010	Patients with non-small cell lung cancer stage IIB / IV incurable following failure of standard therapy for advanced or metastatic disease	Worldwide Clinical Research S.A. (OIC)
Study open, phase II immunization with recMAGE-A3 + AS01B antitumor immunotherapy specific antigen	2010	Subjects with progressive and unresectable MAGE-A3 positive metastatic cutaneous melanoma	GlaxoSmithKline
Phase III clinical trial of vinflunine plus capecitabine versus capecitabine alone	2010	Patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are resistant to taxanes	PIERRE FABRE (ROVAFARM ARGENTINA S. A.)
A prospective, randomized, multicenter, open-label, phase III study of specific active immunotherapy with racotumomab added to the best Clinical support vs. The best clinical support	2010	Patients with advanced non-small cell lung cancer (cpcnp)	Research & Development RA S.A
Phase II trial of escalation of the dose until the appearance of exanthema of erlotinib (Tarceva®) plus gemcitabine	2010	Patients with metastatic pancreatic cancer	Hoffmann – La Roche LTD
A randomized, double-blind, placebo-controlled study evaluating the long-term safety and efficacy of darbepoetin alfa given at 500 μg once every 3 weeks in advanced-stage anemic subjects	2011	Non-small cell lung cancer under treatment with multiple cycles of chemotherapy	AMGEN INC
Randomized, multicenter, double-blind trial comparing the efficacy of ipilimumab added to paclitaxel and carboplatin versus placebo added to paclitaxel and carboplatin	2011	With stage IV / recurrent non-small cell lung cancer (NSCLC)	Eisai / ICON
A randomized, double-blind, placebo-controlled, multicenter, Phase 3 Denosumab as adjuvant treatment for women	2011	Early stage breast cancer with a high risk of recurrence	Quintiles/Amgen Inc
Phase 3, randomized, double-blind, placebo-controlled study of ARQ 197 plus Erlotinib versus Placebo plus Erlotinib	2011	Subjects with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC) treated previously	Daiichi Sankyo Pharma Development - ICON
A randomized, double-blind, multicenter, placebo-controlled study of lapatinib adjuvant	2011	Women with breast cancer with ErbB2 overexpression in early stage	GlaxoSmithKline
A randomized, open-label, phase III study of taxane-based chemotherapy with lapatinib or trastuzumab as first-line therapy	2011	Women with metastatic breast cancer her2 / neu positive	GlaxoSmithKline
Phase III study of gastric, esophageal or gastroesophageal adenocarcinoma	2011	Herb2 positivo, avanzado o metastásico, tratado con capecitabina más oxaliplatino, con o sin lapatinib	GlaxoSmithKline
A phase III study comparing the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus AI versus lapatinib plus AI as first-line therapy	2011	Postmenopausal women with HER2 positive, hormone receptor positive metastatic breast cancer (CMM) who have received trastuzumab and endocrine therapy in the neoadjuvant and / or adjuvant setting	GlaxoSmithKline
A randomized, double-blind, placebo-controlled Phase III study to evaluate the safety and efficacy of pazopanib as adjunctive therapy	2011	Subjects with localized or locally advanced renal cell carcinoma, after nephrectomy	GlaxoSmithKline
Everolimus phase III multicenter, randomized, double-blind, placebo-controlled study combined with Trastuzumab and Paclitaxel as first-line therapy	2011	Women with locally advanced or metastatic HER2 positive breast cancer	NOVARTIS
A randomized, double-blind, phase II multicentre, placebo-controlled study of everolimus given daily in combination with trastuzumab and vinorelbine in pretreated women	2011	Locally advanced or metastatic breast cancer with overexposure of HER2 / ne	NOVARTIS
Efficacy and safety of oral netupitant given in combination with palonosetron and dexamethasone compared to oral palonosetron and dexamethasone for the prevention of nausea and vomiting	2011	Cancer patients receiving moderately emetogenic chemotherapy	Helsinn Healthcare S.A
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Farletuzumab's Efficacy and Safety (MORAb-003) Administered Once a Week in Combination with Carboplatin and Taxane	2011	Subjects with the First Recurrence of Platinum Sensitive Ovarian Cancer	PPD Argentina S.A.
Randomized, double-blind, phase 3 study of IMC 112B and best supportive care (MCS) versus placebo and MCS	2011	Treatment of gastric adenocarcinoma or metastatic gastroesophageal junction. After progression of disease with first line combination treatment containing platinum or fluoropyrimidin	ImClone LLC/Parexel International S.A
To evaluate the efficacy and safety of T-DM1 in combination with pertuzumab or T-DM1 in combination with pertuzumab placebo (blind for pertuzumab) compared to the combination of trastuzumab plus taxane as first-line treatment	2011	HER2 positive, progressive or recurrent, locally advanced metastatic breast cancer	Hoffmann – La Roche LTD
A randomized, double-blind, placebo-controlled, Phase III study of the effect of GTx-024 on loss of muscle mass	2012	In patients with non-small cell lung cancer who receive first-line chemotherapy based on platinum and a taxane	GTX
A Randomized Phase II, Open Label, Lapatinib-Capecitabine or Lapatinib / Vinorelbine or Lapatinib / Gemcitabine	2012	Metastatic breast cancer with Her2 / neu amplified with progression after taxane treatment	GAICO
Randomized, open-label study of BIBW 2992 in combination with vinorelbine versus trastuzumab in combination with vinorelbine	2012	Metastatic breast cancer with overexpression of HER2 that failed prior treatment with trastuzumab	PAREXEL International S.A / Boehringer Ingelheim
Pivotal study in patients with breast cancer to investigate the efficacy and safety of LA-EP2006 and Neulasta®	2012	Breast cáncer	Sandoz GmbH – i3 Latin America Argentina S.A
Single dose in parallel groups to evaluate the efficacy and safety of oral palonosetron 0.50 mg compared to palonosetron I.V. 0.25 mg administered with dexamethasone for the prevention of nausea and vomiting induced by chemotherapy	2012	Cancer patients receiving highly emetogenic cisplatin-based chemotherapy	Helsinn Healthcare S.A
A multicenter, randomized, double-blind, placebo-controlled study comparing the administration of chemotherapy plus trastuzumab plus placebo versus the administration of chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy	2012	Patients with HER2-positive operable primary breast cáncer	Hoffmann – La Roche LTD
Active comparator, parallel group, performed under internal blind conditions, to examine the efficacy and safety of a single dose of 150 mg Fosaprepitant Dimeglumine intravenously	2012	Prevention of chemotherapy-induced nausea and vomiting (CINV) related to moderately emetogenic chemotherapy	MERCK
Patient CA primary invasive HER2 positive breast, post definitive surgery. Period between surgery and random assignment at least 3 weeks post-surgery and no more than 7 weeks. Adjuvant chemo within the week of randomization	2012	Breast cáncer	Hoffmann – La Roche LTD
PegInterferon Lambda 1a with and without Daclatasvir compared to PegInterferon Alpha 2a, each combined with Ribavirin for the treatment of patients with Chronic Hepatitis C Genotypes 2 and 3 without pretreatmen	2013	Hepatitis	BMS
Pegylated interferon Lambda 1a in combination with Ribavirin and Daclatasvir for the treatment of chronic hepatitis C virus (HCV) genotypes 1, 2, 3 or 4 in HIV coinfected patients who have not received prior treatment	2014	Hepatitis	BMS
Phase III, randomized, double-blind, double-simulated, placebo-controlled, multicenter study to evaluate the efficacy (induction of remission) and safety of Etrolizumab compared to Adalimumab and placebo in patients with moderate to severe ulcerative coli	2016	Ulcerative colitis	ROCHE
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderate to severe active Crohn's disease	2016	Crohn's Disease	ROCHE
Phase 3 multicenter, randomized, double-blind, placebo-controlled trial of oral RPC1063 as induction and maintenance therapy for moderate to severe ulcerative colitis	2016	Ulcerative colitis	RECEPTOS
To assess the safety and efficacy of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction	2011	Heart failure	NOVARTIS
Event-driven, canakinumab administered subcutaneously every 3 months in the prevention of recurrent cardiovascular events in a stable patient following an elevated hsCRP myocardial infarction	2012	Myocardial infarction	NOVARTIS
Fixed combinations of enofibrate / simvastatin 145/20 mg and enofibrato / simvastatin 145/40 mg versus monotherapies with the same drugs in subjects with dyslipidemia with a high risk of cardiovascular disease	2012	Cardiovascular disease	ABBOTT
Cardiovascular safety, and renal microvascular outcomes with linagliptin administered at a dose of 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk	2014	Diabetes mellitus type 2 with high vascular risk	Boehringer Ingelheim
Multicenter and international prospective registry of patients of both sexes with diagnosis of atrial fibrillation	2014	FA	Thrombosis Research Institute
A prospective, randomized, open blinded trial (PROBE) trial to evaluate DUAL antithrombotic therapy with dabigatran etexilate (110 mg and 150 mg bid) plus clopidogrel or ticagrelor compared to the triple therapy strategy with warfarin (INR 2.0 -3.0) plus	2015	FA	Boehringer Ingelheim
A randomized, controlled, 2 x 2 factorial clinical trial to evaluate the safety of Apixaban as compared to a vitamin K antagonist and aspirin compared to aspirin in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary int	2016	FA	BMS
Evaluar la seguridad y la eficacia del ácido zoledrónico en el tratamiento de la osteoporosis en mujeres posmenopáusicas que reciben calcio y vitamina D	2001	OTP	NOVARTIS
To assess the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women receiving calcium and vitamin D	2001	OTP	NOVARTIS
Two different doses of BMS-188667 given IV in Ptes with Active RA while being treated with MTX	2001	AR	BRISTOL
To assess the safety and tolerability of BMS188667 administered IV in pts with active RA with or without concomitant diseases receiving antirheumatic drugs modifying current history of the disease	2003	AR	BRISTOL
To assess the efficacy and safety of BMS-188667 + MTX versus MTX alone with inadequate response to MTX	2004	AR	BRISTOL
Evaluate Abatacept or Infliximab in combination with Methotrexate for the control of disease activity in patients with Rheumatoid Arthritis who present inadequate clinical response to Methotrexate	2005	AR	BRISTOL
To assess the safety and efficacy of oral TAK-715 in the treatment of signs and symptoms of rheumatoid arthritis	2005	AR	PPD
To evaluate the safety and efficacy of Zoledronic Acid in the treatment of OTP in postmenopausal women receiving Calcium and Vit D	2005	OTP	NOVARTIS
Treatment with Tocilizumab (MRA) in pts who completed central studies	2006	AR	ROCHE
Determination of the dose of ATACICEPT, administered IV, ptes with RA and with insufficient response to tto with TNF antagonist	2006	AR	MERCK/SERONO
Dose Search to Evaluate the Effects of BA058 on the Treatment of Postmenopausal Women with OTP	2006	OTP	MDS
To evaluate the efficacy and safety of lyophilized CDP870, an engineered human PEG anti-TNF conjugate, as additional medication to methotrexate, in the treatment of signs and symptoms and prevention of structural damage	2006	AR	QUINTILES
To determine the effect of MRA as monotherapy, compared to a treatment regimen with MTX alone	2006	AR	ROCHE
Open Study of Diacerein (Arthroder) in the Treatment of Osteoarthritis	2006	AR	TRB
To assess the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who maintained methotrexate therapy	2007	AR	ROCHE
Atacicept in patients without previous treatment with anti-TNFα with moderate to severe active Rheumatoid Arthritis (RA) and with inadequate response to methotrexate	2007	AR	MERCK/SERONO
Effect on renal function of ibandronate, given as an i.v. bolus injection, as compared to an i.v. infusion, and alendronate	2007	OTP	ROCHE
Concept of SB-751689 in Postmenopausal Men and Women	2007	OTP	GLAXO
Multiple Doses and Pharmacokinetics / Pharmacodynamics of LY2189102	2007	AR	ELI LLIY
OPTIMA protocol for the initiation of treatment with combination therapy of Metotrexate and Adalimumab in patients with RA	2007	AR	ABBOTT
To assess the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis with inadequate response to at least one anti-TNF therapy	2007	AR	ROCHE
To evaluate the safety and efficacy of ocrelizumab in combination Methotrexate (MTX) compared to MTX alone in patients with Untreated rheumatoid arthritis with methotrexate	2007	AR	ROCHE
Rituximab in combination with methotrexate (MTX), compared with methotrexate alone, in patients with active rheumatoid arthritis who have never received MTX	2007	AR	ROCHE
Two Subcutaneous Doses of IPP-201101 More Base Medications, Versus Placebo More Base Medications	2007	LES	IMMUPHARMA
Duloxetine versus Placebo in the Treatment of Chronic Low Back Pain	2007	LUMBALGIA	ELI LILLY
To evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of BG9924 administered in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to conventional therapy with DMARD	2007	AR	PPD ARGENTINA
To investigate the clinical efficacy of ofatumumab in subjects with active RA with inadequate response to treatment with MTX	2008	AR	I3
Pts who have recently experienced an outbreak of systemic lupus erythematosus	2008	LES	MERCK
Combination of prolonged-release Tramadol hydrochloride and Meloxicam QD in the treatment of moderate to moderately severe pain	2008	OA	GLOBAL IQ
To assess the safety and efficacy of BG9924 administered in combination with Methotrexate in rheumatoid arthritis patients previously enrolled in the 104RA202 Study	2008	AR	PPD ARGENTINA
Pts who have not received prior biological treatment	2009	AR	ELI LLIY
Pts receiving concomitant MTX and an inadequate response to treatment with a TNFα inhibitor	2009	AR	OMNICARE
To assess the long-term efficacy and safety of 6-year and 9-year treatment with Zoledronic Acid in postmenopausal women with osteoporosis	2009	OTP	NOVARTIS
Tranilast with MTX concomitant compared to MTX	2010	AR	GLOBAL IQ
Subcutaneous administration (SC) of Tocilizumab in comparison to the administration (IV) of Tocilizumab, in combination with traditional anti-rheumatic disease modifying drugs (DMARD), in moderate to severe active RA	2011	AR	ROCHE
Inadequate response to a TNF-alpha antagonist	2011	AR	ASTRA ZENECA
Inadequate response to MTX	2011	AR	ASTRA ZENECA
Long-term extension of the previous OSKIRAS	2011	AR	ASTRA ZENECA
To assess the efficacy and safety of LY2127399 in patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to treatment with methotrexate	2011	AR	ELI LILLY
AR Active who have presented an inadequate response to MTX monotherapy	2011	AR	KENDLE